PTGDS and COVID-19: By and large, current evidence is insufficient to support if PGs or, in other words, NSAIDs have beneficial or deleterious actions on SARS‐CoV‐2 infection, development, and disease progression, although PGE2 (maybe also PGD2) is likely to be involved in inhibiting host antiviral responses and development of hyperinflammation in patients with COVID‐19.